Development and initial characterization of a mitomycin C-resistant colon cancer cell line variant.
Resistance may limit the clinical usefulness of a variety of chemotherapeutic drugs, including mitomycin C (MMC). In order to study resistance to MMC, a variant of the HT-29 human colon cell line was isolated by exposure to repeated doses of MMC. The 95% inhibitory concentration of MMC for this isolate (HT-29R13) was found to be approximately twice that for the parent line. The level of resistance did not increase with additional drug exposure, and resistance was stable for at least 6 months in the absence of drug exposure. HT-29R13 cells exhibit cross-resistance to melphalan and 5-FU but not to doxorubicin, cis-platinum, or etoposide. HT-29R13 cells are characterized by slightly decreased plating efficiency and slightly increased total protein compared with the parent line. This model of stable, low-level MMC resistance with an unusual cross-resistance pattern may prove useful for the study and characterization of MMC resistance mechanisms.
Perry
R R
RR
Department of Surgery, Eastern Virginia Medical School, Norfolk 23507-1912.
Greaves
B R
BR
Kang
Y
Y
D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology*; D004351:Drug Resistance; D006801:Humans; D016685:Mitomycin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects*
D016685:Mitomycin